Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.
本发明公开了由式(I)表示的取代
吡唑化合物或其盐,其中R1为—CH(OH)—CH(R4)—(A)n—Y,—
CH2—CH(R4)—(A)n—Y,—CO—B1—A—Y或类似物(其中A为较低的烷基;Y为芳基,可以被卤素等取代;R4为氢原子或较低烷基基团;B1为—CH(R4)—或—N(R4)—;n为0或1);R2为氢原子,可以被羟基等取代的较低烷基基团,或芳基烷基基团;R3为可以被卤素等取代的苯基或
吡啶基;Q为
吡啶基或
喹啉基。这些取代的
吡唑化合物或其盐具有优异的p38
MAP激酶抑制作用,因此在预防或治疗肿瘤坏死因子α相关疾病、白细胞介素1相关疾病、白细胞介素6相关疾病或环氧合酶II相关疾病方面非常有用。